SG11201901954XA - 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof - Google Patents
8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereofInfo
- Publication number
- SG11201901954XA SG11201901954XA SG11201901954XA SG11201901954XA SG11201901954XA SG 11201901954X A SG11201901954X A SG 11201901954XA SG 11201901954X A SG11201901954X A SG 11201901954XA SG 11201901954X A SG11201901954X A SG 11201901954XA SG 11201901954X A SG11201901954X A SG 11201901954XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- applicant
- rule
- bda
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property 111111411 01E101011M 3E1 0 011101 IMI 100 11101101110 11110 1111 OEN Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2018/046409 Al 15 March 2018 (15.03.2018) WIP0 I PCT (51) International Patent Classification: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, CO7D 471/04 (2006.01) A61P 29/00 (2006.01) SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, A61K 31/437 (2006.01) TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (21) International Application Number: (84) Designated States (unless otherwise indicated, for every PCT/EP2017/072034 kind of regional protection available): ARIPO (BW, GH, (22) International Filing Date: GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, 02 September 2017 (02.09.2017) UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (25) Filing Language: English EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, (26) Publication Language: English MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (30) Priority Data: KM, ML, MR, NE, SN, TD, TG). PCT/CN2016/098215 06 September 2016 (06.09.2016) CN Declarations under Rule 4.17: — as to applicant's entitlement to apply for and be granted a (71) Applicant (for all designated States except US): F. HOFF- patent (Rule 4.17(ii)) MANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse — as to the applicant's entitlement to claim the priority of the 124, 4070 Basel (CH). earlier application (Rule 4.17(iii)) (71) Applicant (for US only): GENENTECH, INC. [US/US]; — of inventorship (Rule 4.17(iv)) — 1 DNA Way, South San Francisco, California 94080 (US). Published: (72) Inventors: GOODACRE, Simon Charles; 8/9 Spire — with international search report (Art. 21(3)) = Green Centre, Flex Meadow, Harlow Essex CM195TR = (GB). ZAK, Mark; c/o Genentech, Inc., 1 DNA Way, South _ San Francisco, California 94080 (US). ROMERO, F. An- thony; Genentech, Inc., 1 DNA Way, South San Fran- = c/o cisco, California 94080 (US). CHENG, Yun-Xing; 6 Tai- _ he Road, BDA, Beijing 100176 (CN). CHENG, Limin; 6 = Tai-he Road, BDA, Beijing 100176 (CN). HUA, Rongbao; = = 6 Tai-he Road, BDA, Beijing 100176 (CN). (74) Agent: SCHIRLIN, Julien; Grenzacherstrasse 124, 4070 = Basel (CH). (81) Designated States (unless otherwise indicated, for every = — kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = _ DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, _ = HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, = KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, = MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, = (54) Title: 8-(AZETIDIN-1-YL)41,2,4]TRIAZOLO[1,5-A]PYRIDINYL COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF Il R5 R5 4 C:r N 'N ''' R4 H N \" \"L-....-. 0 © 0 N N 1 1' N 3 RA N 0 N ---- 3 R 1 \" N 1 1' n R ic © ---.... N NC C Rz Il R 6 (1) R 6 (II) 0 N C (57) : Compounds of Formuula (I) and (II), or a stereoisomer, tautomer, solvate, prodrug or salt thereof, and methods of use as Janus kinase inhibitors are described herein.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2016098215 | 2016-09-06 | ||
| PCT/EP2017/072034 WO2018046409A1 (en) | 2016-09-06 | 2017-09-02 | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901954XA true SG11201901954XA (en) | 2019-04-29 |
Family
ID=59761965
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901954XA SG11201901954XA (en) | 2016-09-06 | 2017-09-02 | 8-(azetidin-1-yl)-[1,2,4]triazolo[1,5-a]pyridinyl compounds, compositions and methods of use thereof |
Country Status (19)
| Country | Link |
|---|---|
| US (3) | US20190202822A1 (en) |
| EP (2) | EP4198036A1 (en) |
| JP (1) | JP7050761B2 (en) |
| KR (1) | KR20190045302A (en) |
| CN (1) | CN109890817B (en) |
| AU (1) | AU2017324281A1 (en) |
| BR (1) | BR112019004486A2 (en) |
| CA (1) | CA3035712A1 (en) |
| CL (1) | CL2019000568A1 (en) |
| CO (1) | CO2019002171A2 (en) |
| CR (1) | CR20190118A (en) |
| IL (1) | IL265153A (en) |
| MA (1) | MA46176A (en) |
| MX (1) | MX2019002627A (en) |
| PE (1) | PE20190632A1 (en) |
| PH (1) | PH12019500478A1 (en) |
| RU (1) | RU2019109570A (en) |
| SG (1) | SG11201901954XA (en) |
| WO (1) | WO2018046409A1 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020257143A1 (en) * | 2019-06-18 | 2020-12-24 | Genentech, Inc. | Pyrazolopyrimidine aryl ether inhibitors of jak kinases and uses thereof |
| GB202213164D0 (en) | 2022-09-08 | 2022-10-26 | Cambridge Entpr Ltd | Novel compounds, compositions and therapeutic uses thereof |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU650953B2 (en) | 1991-03-21 | 1994-07-07 | Novartis Ag | Inhaler |
| US5543523A (en) | 1994-11-15 | 1996-08-06 | Regents Of The University Of Minnesota | Method and intermediates for the synthesis of korupensamines |
| WO1997002289A1 (en) | 1995-07-06 | 1997-01-23 | Zeneca Limited | Peptide inhibitors of fibronectine |
| US6248713B1 (en) | 1995-07-11 | 2001-06-19 | Biogen, Inc. | Cell adhesion inhibitors |
| YU25500A (en) | 1999-05-11 | 2003-08-29 | Pfizer Products Inc. | Process for the synthesis of nucleosite analogues |
| GB0028383D0 (en) | 2000-11-21 | 2001-01-03 | Novartis Ag | Organic compounds |
| EP1241176A1 (en) | 2001-03-16 | 2002-09-18 | Pfizer Products Inc. | Purine derivatives for the treatment of ischemia |
| DE60214428T2 (en) | 2001-12-20 | 2007-09-20 | Bayer Healthcare Ag | 1, 4-DIHYDRO-1, 4-DIPHENYLPYRIDINE DERIVATIVES |
| SE0302487D0 (en) | 2003-09-18 | 2003-09-18 | Astrazeneca Ab | Novel compounds |
| GB0502258D0 (en) | 2005-02-03 | 2005-03-09 | Argenta Discovery Ltd | Compounds and their use |
| MX2010014005A (en) | 2008-06-20 | 2011-02-15 | Genentech Inc | Triazolopyridine jak inhibitor compounds and methods. |
| WO2010010184A1 (en) * | 2008-07-25 | 2010-01-28 | Galapagos Nv | [1, 2, 4] triazolo [1, 5-a] pyridines as jak inhibitors |
| US8501936B2 (en) | 2009-06-05 | 2013-08-06 | Cephalon, Inc. | Preparation and uses of 1,2,4-triazolo [1,5a] pyridine derivatives |
| US8575336B2 (en) | 2011-07-27 | 2013-11-05 | Pfizer Limited | Indazoles |
| ES2845210T3 (en) * | 2013-05-17 | 2021-07-26 | Incyte Corp | Bipirazole derivatives as JAK inhibitors |
| SG11201601707PA (en) * | 2013-09-05 | 2016-04-28 | Hoffmann La Roche | Triazolopyridine compounds, compositions and methods of use thereof |
| JP2018507236A (en) * | 2015-03-04 | 2018-03-15 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Triazolopyridine compounds and methods of use thereof |
-
2017
- 2017-09-02 KR KR1020197009674A patent/KR20190045302A/en not_active Application Discontinuation
- 2017-09-02 BR BR112019004486A patent/BR112019004486A2/en not_active Application Discontinuation
- 2017-09-02 MX MX2019002627A patent/MX2019002627A/en unknown
- 2017-09-02 AU AU2017324281A patent/AU2017324281A1/en not_active Abandoned
- 2017-09-02 SG SG11201901954XA patent/SG11201901954XA/en unknown
- 2017-09-02 CA CA3035712A patent/CA3035712A1/en not_active Abandoned
- 2017-09-02 CR CR20190118A patent/CR20190118A/en unknown
- 2017-09-02 MA MA046176A patent/MA46176A/en unknown
- 2017-09-02 JP JP2019512740A patent/JP7050761B2/en active Active
- 2017-09-02 PE PE2019000482A patent/PE20190632A1/en unknown
- 2017-09-02 RU RU2019109570A patent/RU2019109570A/en not_active Application Discontinuation
- 2017-09-02 EP EP23150608.0A patent/EP4198036A1/en active Pending
- 2017-09-02 CN CN201780066617.5A patent/CN109890817B/en active Active
- 2017-09-02 EP EP17761254.6A patent/EP3510030B1/en active Active
- 2017-09-02 WO PCT/EP2017/072034 patent/WO2018046409A1/en unknown
-
2019
- 2019-03-04 IL IL265153A patent/IL265153A/en unknown
- 2019-03-05 US US16/293,129 patent/US20190202822A1/en not_active Abandoned
- 2019-03-05 PH PH12019500478A patent/PH12019500478A1/en unknown
- 2019-03-06 CL CL2019000568A patent/CL2019000568A1/en unknown
- 2019-03-08 CO CONC2019/0002171A patent/CO2019002171A2/en unknown
-
2020
- 2020-05-08 US US16/870,602 patent/US20200270248A1/en not_active Abandoned
-
2023
- 2023-04-07 US US18/297,546 patent/US20230242530A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019002627A (en) | 2019-10-30 |
| CL2019000568A1 (en) | 2019-07-12 |
| EP3510030B1 (en) | 2023-03-22 |
| CN109890817B (en) | 2022-06-17 |
| CN109890817A (en) | 2019-06-14 |
| CA3035712A1 (en) | 2018-03-15 |
| EP4198036A1 (en) | 2023-06-21 |
| RU2019109570A (en) | 2020-10-08 |
| WO2018046409A1 (en) | 2018-03-15 |
| JP2019526593A (en) | 2019-09-19 |
| MA46176A (en) | 2019-07-17 |
| AU2017324281A1 (en) | 2019-03-21 |
| US20190202822A1 (en) | 2019-07-04 |
| PH12019500478A1 (en) | 2019-12-02 |
| BR112019004486A2 (en) | 2019-05-28 |
| CR20190118A (en) | 2019-04-30 |
| JP7050761B2 (en) | 2022-04-08 |
| US20200270248A1 (en) | 2020-08-27 |
| PE20190632A1 (en) | 2019-04-26 |
| KR20190045302A (en) | 2019-05-02 |
| EP3510030A1 (en) | 2019-07-17 |
| IL265153A (en) | 2019-05-30 |
| US20230242530A1 (en) | 2023-08-03 |
| CO2019002171A2 (en) | 2019-05-21 |
| RU2019109570A3 (en) | 2020-10-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201900163PA (en) | Macrocycle kinase inhibitors | |
| SG11201805044WA (en) | Compounds useful as kinase inhibitors | |
| SG11201811414TA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201903182XA (en) | 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer | |
| SG11201808682XA (en) | Silicone atoms containing ivacaftor analogues | |
| SG11201810683VA (en) | Process for preparing n-(5-(3-(7-(3-fluorophenyl)-3h-imidazo[4,5-c]pyridin-2-yl)-1h-indazol-5-yl)pyridin-3-yl)-3-methylbutanamide | |
| SG11201903487SA (en) | PROCESS FOR THE PREPARATION OF PYRAZOLO[1,5-a]PYRIMIDINES AND SALTS THEREOF | |
| SG11201810366WA (en) | 3-oxo-2,6-diphenyl-2,3-dihydropyridazine-4-carboxamides | |
| SG11201408821SA (en) | Selective pi3k delta inhibitors | |
| SG11201810628XA (en) | Nasal pharmaceutical compositions with a porous excipient | |
| SG11201408133TA (en) | Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
| SG11201808237UA (en) | Substituted indole compound derivatives as dengue viral replication inhibitors | |
| SG11201903483VA (en) | Compositions and methods for treating ezh2-mediated cancer | |
| SG11201811225RA (en) | Ar+ breast cancer treatment methods | |
| SG11201908602UA (en) | Combination therapy for the treatment of solid and hematological cancers | |
| SG11201808566WA (en) | Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide | |
| SG11201808138YA (en) | Substituted indole derivatives as dengue viral replication inhibitors | |
| SG11201808676RA (en) | Methods of treating pediatric cancers | |
| SG11201408750VA (en) | NOVEL FUSED PYRIDINE DERIVATIVES USEFUL AS c-MET TYROSINE KINASE INHIBITORS | |
| SG11201810965YA (en) | 1h-pyrazolo[4,3-b]pyridines as pde1 inhibitors | |
| SG11201909807TA (en) | Methods of manufacturing of niraparib | |
| SG11201909735YA (en) | Therapeutic compounds and compositions, and methods of use thereof | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201808221QA (en) | 1,5-dihydro-4h-pyrazolo[3,4-d]pyrimidin-4-ones and 1,5-dihydro-4h-pyrazolo[4,3-c]pyridin-4-ones as pde1 inhibitors |